Evolus (NASDAQ:EOLS) Reaches New 52-Week High – What’s Next?

Evolus, Inc. (NASDAQ:EOLS)’s stock price reached a new 52-week high on Wednesday . The stock traded as high as $8.44 and last traded at $8.4140, with a volume of 99211 shares changing hands. The stock had previously closed at $8.18.

Analysts Set New Price Targets

Several brokerages have commented on EOLS. Weiss Ratings upgraded shares of Evolus from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, June 15th. BTIG Research reiterated a “buy” rating and set a $13.00 price target on shares of Evolus in a research report on Wednesday, June 17th. Finally, Wall Street Zen raised shares of Evolus from a “hold” rating to a “buy” rating in a research note on Saturday, August 8th. Four analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $14.50.

Evolus Price Performance

The company has a 50 day moving average of $6.72 and a two-hundred day moving average of $5.69. The company has a market capitalization of $549.87 million, a PE ratio of -16.01 and a beta of 1.35.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of EOLS. Larson Financial Group LLC boosted its stake in Evolus by 136.6% during the fourth quarter. Larson Financial Group LLC now owns 4,914 shares of the company’s stock worth $33,000 after acquiring an additional 2,837 shares in the last quarter. Meeder Asset Management Inc. purchased a new stake in shares of Evolus in the 4th quarter worth approximately $34,000. Wexford Capital LP bought a new position in Evolus during the 3rd quarter valued at approximately $37,000. Legal & General Group Plc purchased a new position in Evolus during the second quarter valued at $40,000. Finally, Aquatic Capital Management LLC purchased a new position in Evolus during the third quarter valued at $48,000. 90.69% of the stock is currently owned by institutional investors.

About Evolus

Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.

The company’s flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.